Recent Company News

• 08:32 AM ET Oct 20, 2025
  

  EDAP TMS enters into a €36M multi-tranche credit facility with the EIB ($2.24, 0.00)

• 09:50 AM ET Oct 17, 2025
  

  Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

• 09:30 AM ET Sep 09, 2025
  

  Transcript Intelligence: EDAP TMS at H.C. Wainwright Global Investment Conference

• 07:07 AM ET Sep 08, 2025
  

  EDAP TMS Receives HIFU Reimbursement for Prostate Cancer in France ($2.52, 0.00)

• 07:08 AM ET Aug 28, 2025
  

  EDAP TMS reports Q2 EPS (€0.15) vs FactSet (€0.18) [1 est] ($1.58, 0.00)

• 07:06 AM ET Jul 01, 2025
  

  EDAP TMS announces transition to U.S. domestic filer status from foreign private issuer effective Jan 2026 ($1.65, 0.00)

• 05:45 PM ET May 15, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 12:49 PM ET May 15, 2025
  

  EDAP TMS downgraded to neutral from overweight at Piper Sandler (timing uncertain) ($1.78, -0.38)

• 07:10 AM ET May 15, 2025
  

  EDAP TMS reports Q1 EPS (€0.19) vs FactSet (€0.15) [3 est, (€0.16)-(0.14)] ($2.16, 0.00)

• 07:05 AM ET Apr 29, 2025
  

  EDAP announces results from the FARP randomized controlled trial presented at the AUA annual meeting ($2.18, 0.00)